Compare Novavax Inc (NVAX) vs Novartis AG (NVS) Price & Performance

Novavax IncTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Novartis AG — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 223.3× Novavax Inc's market cap, and Novartis AG pays a 3.17% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

	NVAX	NVS
Market Cap	$1.30B	$290.25B
Sector	Health	Health
52-Week High	$11.19	$168.62
52-Week Low	$6.22	$113.50
Enterprise Value	$800.50M	$330.27B
Dividend Yield	—	3.17%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVAX

View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.